Targeted Intracellular Delivery Summit Hilton Boston Back Bay, Boston

It has long been understood that the ability to deliver therapeutic cargos to cytosolic sites of action in target tissue could unlock access to previously undruggable targets, whilst enabling the development of safer and efficacious drugs.

Now, advances in nanomedicine technology, the LNP-enabled mRNA vaccine and modern medicine’s shift towards a more personalized model are fuelling excitement amongst drug developers as they position their pipelines towards utilizing novel delivery systems which effectively engage previously elusive intracellular targets.

With mounting investments, industry collaborations and interest in leveraging next-generation nano vehicles, from LNP’s, liposomes, EV’s, polymeric nanoparticles (and beyond!), new avenues have been opened for optimizing the therapeutic index of novel pipelines, from antisense oligonucleotides, siRNA, mRNA and DNA delivery to peptide protein drugs.

It’s timely for the Targeted Intracellular Delivery Summit to arrive as your only industry dedicated forum, focussed on accelerating the mechanistic understanding and potential of much-needed intracellularly delivery technologies through exploiting an advanced understanding of membrane biology and biological barriers.

Uniting the leading minds of large pharma, biotech and academia, unite with Formulation, Chemistry, Delivery and Biology as industry showcases the pioneering discoveries, critical findings and novel approaches fast-tracking promising candidates towards the clinic.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

Speakers: Allen Horhota, Senior Director, Head of Delivery, Orna Therapeutics, Avidor Shulman, Chief Technology Officer, Biond Biologics, Ben Spangler, Senior Scientist, BioMarin Pharmaceutical, Christopher Locher, Chief Executive Officer, Versatope, David Guay, Vice President, Innovation and Technology, Feldan Therapeutics, De-Min Zhu, President and Chief Executive Officer, Cureport, Ernst Wagner, Professor, Ludwig- Maximilians- Universität München, Fionnuala Lane, Program Director, Targeted Drug Delivery Series, Gibeom Kim, Laboratory Director, ShiftBio, Guy Hermans, Chief Executive Officer, Sapreme Technologies, Heinrich Haas, Vice President, RNA Formulation and Drug Delivery, BioNTech, James Ferguson Chief Medical Officer, Matinas BioPharma, Kalina Paunovska, Co-Founder, Nava Therapeutics, Manmohan Singh, Chief Technology Officer, Beam Therapeutics, Michael Munson, Senior Research Scientist, AstraZeneca, Niren Murthy, Professor, Department of Bioengineering, University of California, Berkeley, Qi-Ying Hu, Vice President, Head of Formulation and Delivery, Omega Therapeutics, Rui Zhang, Associate Director, LNP Formulation, Tessera Therapeutics, Sean Bedingfield, Research Engineer, Lilly Genetic Medicine, Eli Lilly and Company, Shalom Goldberg, Senior Principal Scientist, Johnson and Johnson